Vyome Holdings, Inc Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Vyome Holdings, Inc price/book ratio for the quarter ending 2025-09-30 was 5.48, a 97.95% decline year-over-year.
- Vyome Holdings, Inc price/book ratio for the quarter ending 2025-06-30 was 4.39, a 99.96% decline year-over-year.
- Vyome Holdings, Inc price/book ratio for the quarter ending 2025-03-31 was 3.91, a 99.93% decline year-over-year.
- Vyome Holdings, Inc price/book ratio for the quarter ending 2024-09-30 was 267.76, a 87.80% decline year-over-year.
- Vyome Holdings, Inc price/book ratio for fiscal 2025 was 5.48, a 97.95% decline from fiscal 2024.
- Vyome Holdings, Inc price/book ratio for fiscal 2024 was 267.76.
- Vyome Holdings, Inc price/book ratio for fiscal 2023 was 88.01, a 98.41% decline from fiscal 2022.
- Vyome Holdings, Inc price/book ratio for fiscal 2022 was 5,544.2, a 44.91% increase from fiscal 2021.
- Available history
- 2016-12-31 to 2025-09-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |